

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/061453 A1

(51) International Patent Classification⁷: **C07D 207/06**,
211/22, 211/46, 207/12, 207/08, 211/18, 211/38, 207/10,
207/46, 211/94, A61K 31/445, A61P 35/00

WC1N 1AX (GB). **TEESDALE-SPITTLE, Paul, Henry**
[GB/NZ]; School of Biological Sciences, Te Kura Matau-
ranga Koiora, Victoria University of Wellington, P.O.Box
600, Wellington (NZ).

(21) International Application Number:
PCT/GB2004/005390

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).

(22) International Filing Date:
22 December 2004 (22.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0329820.5 23 December 2003 (23.12.2003) GB
0330011.8 24 December 2003 (24.12.2003) GB

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (*for all designated States except US*): **SCHOOL
OF PHARMACY, UNIVERSITY OF LONDON**
[GB/GB]; 29-39 Brunswick Square, London WC1N 1AX
(GB).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PATTERSON, Lau-
rence, Hylton** [GB/GB]; School Of Pharmacy, University
Of London, 29-39 Brunswick Square, London WC1N
1AX (GB). **PORS, Klaus** [DK/GB]; School of Pharmacy,
University of London, 29-39 Brunswick Square, London


Published:
— with international search report

[Continued on next page]

(54) Title: ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS



(I)



(II)

(57) Abstract: Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R¹ to R⁴ are each selected from the group consisting of H, C₁₋₄ alkyl, X¹, -NHR⁰N (R⁵)₂ in which R⁰ is a C₁₋₁₂ alkanediyl and each R⁵ is H or optionally substituted C₁₋₄ alkyl, and a group of formula (II) in which at least one of R⁶, R⁷ and R⁸ is selected from X², and X² substituted C₁₋₄ alkyl and any others are H or C₁₋₄ alkyl; R⁹ is selected from H, C₁₋₄ alkyl, X² and X² substituted C₁₋₄ alkyl; m is 0 or 1; n is 1 or 2; X¹ is a halogen atom, a hydroxyl group, a C₁₋₆ alkoxy group, an aryloxy group or an acyloxy group; and X² is a halogen atom, a hydroxyl group, a C₁₋₆ alkoxy group, an aryloxy group or an acyloxy group; provided that at least one of R¹ to R⁴ is a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives. The amine compounds are cytotoxic and may be used as alkylating agents having topoisomerase II inhibiting activities in cancer therapy.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.